“Early and Maintained Response Levels in Psoriasis Patients Treated With Tildrakizumab”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s41, https://doi.org/10.25251/skin.4.supp.41.